Introduction
The presence of diabetes mellitus in the setting of an acute myocardial infarction is a marker of a poor prognosis [1] [2] [3] [4] [5] [6] [7] . The reason for this observation is not well understood. Some studies have shown more extensive and severe atherosclerosis in patients with coronary artery disease and diabetes mellitus than in patients without diabetes mellitus, but this is not a universal finding [1, 8] . The possibility that the metabolic disturbance in itself could have critical importance in the evolving infarction has attracted widespread interest and has led to studies which intervene with insulin and glucose in patients with an acute myocardial infarction. Recently, the Randomised Trial of Insulin-Glucose Infusion followed by Subcutaneous Insulin Treatment in Diabetic Patients with Acute Myocardial Infarction (the DIGAMI trial) was performed to investigate whether insulin and glucose administered during the acute phase of an infarction and continued for at least 3 months would improve short-term mortality [11] . The finding in this study was an improvement in long-term mortality and no improvement in short-term mortality [11] . Further insight into the role of intervention in patients with diabetes mellitus may be obtained by studying the time course of the risk associated with the metabolic disease.
If diabetes mellitus carried a very different impact in the years following an acute myocardial infarction, the interpretation of intervention may need to be modified accordingly. For this reason, we have studied the development of risk associated with diabetes mellitus after an acute myocardial infarction in two cohorts of patients. One cohort was selected to provide very long-term follow-up and the other cohort had a shorter follow-up to ensure modern intervention with thrombolytic therapy.
Subjects and Methods

Patients
The Glostrup cohort has been described in detail previously [12] . Glostrup University Hospital, Copenhagen, Denmark serves a population of approximately 250 000 inhabitants. The coronary care unit receives all cardiac emergencies from the uptake area. Between 1979 Between and 1983 Between , 1954 consecutive patients admitted with an acute myocardial infarction were included in the study. None of the patients received thrombolytic agents or were subjected to interventions with beta-blockers or aspirin, since this was not part of the routine in the department at the time of inclusion. During the entire period the chief physician reviewed all hospital files, and patient data concerning the presence of acute myocardial infarction and infarct-related complications were prospectively recorded according to strict criteria [12] . The diagnosis of acute myocardial infarct was based on the World Health Organization criteria requiring that two out of three of the following conditions were present: chest pain and/or typical electrocardiographic changes and/or a transient rise in serum creatinine kinase isoenzyme MB concentration. Patients with a prior diagnosis of diabetes mellitus as well as those for whom the diagnosis was made in relation to the acute myocardial infarction were considered as having diabetes mellitus. A diagnosis of congestive heart failure was based on typical clinical findings. Patients were classified as having a previous myocardial infarction if they had typical changes in ECG and/or a clear documentation of a myocardial infarction from hospital files prior to the index infarction.
The cohort from the Trandolapril Cardiac Evaluation (TRACE) trial has been described in detail in a previous report [13] . In brief, 6676 consecutive patients with acute myocardial infarction were screened in 27 Danish coronary care units. The diagnosis of an acute infarction required that typical symptoms and/or ECG changes were accompanied by an increase in cardiac enzymes to at least twice the upper normal limit. The screening procedure took place between 1 and 6 days after the initial symptoms. All patients underwent echocardiography in order to quantify left ventricular systolic function as wall motion index [14] . The diagnosis of diabetes mellitus was based on the patient's history.
Follow-up
Follow-up was carried out via the Danish Central Personal Register in 1993 for patients from the first cohort. Information on survival of patients from the TRACE trial was obtained in October 1997. Survival data were available for all except three patients, the latter having misrecorded admission or birth dates.
Analysis
Univariate comparisons of discrete variables were performed by the chi-squared test and comparisons of continuous variables by the Mann-Whitney test. The probability of survival in various patient subgroups was estimated by the Kaplan-Meier method. Multivariate comparisons of the influence of several factors on survival was performed using the Cox proportional hazard method. A single model including all potentially relevant parameters as covariates was used. It was checked graphically (Log-Log (survival)), that the proportional hazard assumption was valid. Hazard ratio and 95% confidence limits were calculated from the proportional hazard model as exp (parameter estimate). In this paper relative risk is the term used for hazard ratio. For continuous variables this represents the increased risk associated with an increment of 1 of the variable in question. The SAS (SAS Institute, Cary, U.S.A.) statistical package was used for calculations.
Results
Baseline risk factors for coronary heart disease and in-hospital complications in patients with and without diabetes mellitus from the two study populations are shown in Table 1 . A similar frequency of anterior infarct location was found in patients with and without diabetes mellitus. In both the Glostrup and the TRACE cohorts, patients without diabetes mellitus had higher maximal creatinine kinase isoenzyme MB values than patients with diabetes mellitus. The overall 10-year mortality rate in patients with diabetes mellitus from the Glostrup cohort was higher (90%) than the rate in the patients without diabetes mellitus (65%; P<0·001). Similarly, the 5-year mortality rate in patients with diabetes mellitus from the TRACE cohort was higher (62%) than the rate in patients without diabetes mellitus (38%; P<0·0001).
Further examination of the influence of diabetes mellitus on survival in both cohorts was carried out using proportional hazard analyses that included all available data with potential prognostic significance. The results are shown in Table 2 . Age, diabetes mellitus, a history of myocardial infarction, ventricular fibrillation and the presence of congestive heart failure all had an independent adverse impact on long-term mortality in patients from both cohorts.
In order to evaluate the time-related influence of diabetes mellitus and other risk factors on mortality, the Male gender  1·1  0·98-1·26  0·11  1·04  0·97-1·14  0·25  Hypertension  1·06  0·9-1·3  0·54  1·2  1·1-1·3  0·0001  Previous infarct  1·4  1·2-1·6  0·0001  1·1  1·0-1·1  0·006  Smoking  ---1·05  1·0-1·10  0·057  Anterior infarct  1·0  0·93-1·08  0·93  0·9  0·82-0·97  0·01  CHF  2·7  2·4-3·1  0·0001  1·8  1·6-1·9  0·0001  VF  1·4  1·2-1·7  0·0001  1·7  1·5-1·9  0·0001  Atrial fibrillation  1·0  0·9-1·2  0·8  1·3  1·2-1·5  0·0001  Thrombolysis  ---0·7  0·7-0·8  0·0001  Aspirin  ---0·8  0·8-0·9  0·0001  WM  ---0·4  0·4-0·5  0·0001 Relative risk for continuous variables age given per unit. Total number of patients in the Glostrup cohort=1954 and in the trace trial=6676. CHF=congestive heart failure. VF=ventricular fibrillation. WM=wall motion index.
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above proportional hazard models were repeated for each of the following periods: for the Glostrup cohort, days 0-30, month 2-year 3, years 4-6 and years 7-9; for the TRACE cohort, days 0-30, month 2-year 3 and years 4-6. Since information concerning wall motion index and thrombolysis became available in the patients from the TRACE cohort, it was desirable to include these important factors in the proportional hazard model. The results are shown in Table 3 and Table 4 . The influence of diabetes mellitus and concomitant risk factors on survival was complex. As shown in Table 3 and Table 4 diabetes mellitus had an increasing adverse effect on survival in the late follow-up period after an acute myocardial infarction. In order to evaluate whether thrombolytic therapy had some influence on the time-related effect of diabetes on mortality, an additional proportional hazard analysis was made for those patients who did and did not receive thrombolysis in the TRACE cohort. The timedependent effect of diabetes on 6-year survival was similar in both groups.
Discussion
This study shows that the influence of diabetes mellitus on mortality following an acute myocardial infarction is time-dependent. There is no independent influence on short-term mortality, when all available data with potential prognostic significance were included in the multivariate analysis, but thereafter diabetes mellitus is of steadily increasing importance. This finding was consistent in both the cohorts studied and thus the time-dependency of diabetes mellitus on mortality after an acute myocardial infarction was unchanged following the modern intervention strategies that use beta-blockers, aspirin, thrombolytics and ACE inhibitors [1, [4] [5] [6] [7] 15] . All these treatments have reduced mortality substantially but patients with diabetes mellitus still have a very unfavourable outcome after acute myocardial infarction [1, [4] [5] [6] [7] 15] . Differences in the diagnosis of myocardial infarction as well as in the definition of diabetes in the two cohorts had no influence on the main outcome in the current study. It is well known that elevated blood glucose during the acute phase of myocardial infarction may lead to some over-diagnosis of diabetes. In several published papers diabetes mellitus was not found to be an independent risk factor for increased in hospital mortality in acute myocardial infarction [1, 5, 6] , although the in-hospital mortality rates were higher in patients with rather than without diabetes mellitus. Although patient characteristics, the diagnostic criteria of diabetes, treatments and follow-up periods differed in the two cohorts from the pre-thrombolytic and thrombolytic eras, a similar effect of diabetes on mortality was indicated, which further strengthens the findings in the present study. Likewise the timedependent effect of diabetes on 6-year survival in the present study was similar in patients who did and did not receive thrombolysis.
No information on smoking habits was available in the Glostrup cohort. In the TRACE cohort smoking habits did not have independent effect on 6-year survival. Several other studies have shown a similar or even lower prevalence rates of smokers among patients with than among those without diabetes.
The current study does not give any information about the underlying mechanism of the increased risk of diabetes or the development of risk, but it has important consequences for the future evaluation of intervention in this population aimed at diabetes. In the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial no difference was found in 90-min patency rates (TIMI flow grade 2 or 3) between patients with and without diabetes mellitus [1] . This means that the time-related adverse outcome in patients with diabetes, who in advance are more prone to an extensive coronary atherosclerosis, cannot simply be related to early infarct artery patency. A gradually increasing risk is compatible with early as well as late or persistent mechanisms but, regardless of the mechanism or the duration of an intervention, the study shows that the impact should be expected to be apparent only after some time. On the basis of our current observations, it is not surprising that the benefit of early intervention with insulin in the DIGAMI study was only apparent after one year [11] . The survival advantage in the DIGAMI study was maintained for at least 3·5 years in the patients initially treated with glucose-insulin infusion during the stay in hospital [16] . Accordingly, when evaluating different intervention strategies, it is important to consider the long-term outcome of patients with diabetes mellitus rather than to rely on information on short-term prognosis. The lack of short-term risk associated with diabetes observed in the current study could be attributed to arrhythmic and failure deaths on which the metabolic disorder per se may have relative little impact. It is, however, difficult to explain why the long-lasting effects of insulin/glucose therapy in the DIGAMI trial led to improved long-term survival. The results from the present study cannot explain the underlying mechanism. Diabetes may influence the heart and its vessels in acute and chronic coronary artery disease in several ways: the acceleration of coronary atherosclerosis, endothelial dysfunction, alterations in haemostatic mechanisms and perhaps a direct effect of abnormal glucose and free fatty acid metabolism. The consequences are increased reinfarction rate and the development of congestive heart failure in patients surviving the initial myocardial infarction.
It is important to emphasize that specific mode of treatment may have an immediate effect as well as a long-term effect, which may act in opposite directions. For example, a new surgical mode of treatment is more often assessed during a longer period of follow-up because the favourable short-term effect has to compensate for the increased peri-operative morbidity and mortality.
The major conclusion to be drawn from this study is that diabetes mellitus has little or no influence on Diabetes  1·17  0·86-1·58  0·33  1·37  1·03-1·83  0·031  1·97  1·34-2·91  0·0006  2·51  1·55-4·06  0·0002  Age (years)  1·03  1·02-1·04  0·0001  1·04  1·03-1·05  0·0001  1·04  1·03-1·06  0·0001  1·04  1·02-1·06  0·0001  Male gender  1·01  0·80-1·28  0·91  1·00  0·81-1·25  0·97  1·10  0·81-1·50  0·53  1·35  0·91-1·99  0·13  Hypertension  0·63  0·43-0·93  0·02  0·94  0·70-1·27  0·69  1·81  1·30-2·53  0·0004  1·61  1·04-2·50  0·033  Previous infarct  1·22  0·95-1·57  0·12  1·44  1·13-1·83  0·0028  1·72  1·23-2·40  0·0017  1·29  0·80-2·09  0·30  Anterior infarct  1·05  0·92-1·20  0·49  0·94  0·83-1·06  0·31  1·00  0·85-1·19  0·94  1·06  0·86-1·30  0·59  CHF  7·61  5·67-10·2  0·0001  2·49  2·03-3·06  0·0001  1·68  1·25-2·26  0·0006  1·57  1·06-2·33  0·026  VF  2·24  1·72-2·92  0·0001  1·06  0·74-1·52  0·76  0·89  0·52-1·54  0·68  0·79  0·39-1·56  0·49  Atrial fibrillation  0·68  0·50-0·92  0·011  1·34  1·05-1·71  0·020  1·23  0·84-1·79  0·29  1·01  0·61-1·66  0·97 Relative risk for continuous variables are given per unit. Total number of patients in the Glostrup cohort=1954. CHF=congestive heart failure. VF=ventricular fibrillation.
mortality immediately after an acute myocardial infarction but has an important effect on long-term mortality that increases with time. Therefore, evaluation of interventions targeted at diabetes mellitus following an acute myocardial infarction or acute coronary syndromes must be done on a long time scale. Diabetes  1·03  0·81-1·31  0·83  1·43  1·24-1·66  0·0001  1·74  1·36-2·23  0·0001  Age (years)  1·04  1·03-1·05  0·0001  1·05  1·04-1·06  0·0001  1·05  1·04-1·06  0·0001  Male gender  0·81  0·68-0·97  0·021  1·14  1·01-1·28  0·031  1·10  0·91-1·32  0·33  Hypertension  1·15  0·95-1·39  0·16  1·21  1·07-1·37  0·002  1·08  0·88-1·31  0·47  Previous infarct  0·86  0·76-0·98  0·018  1·19  1·11-1·27  0·0001  1·09  0·96-1·24  0·19  Smoking  1·05  0·94-1·67  0·38  1·02  0·96-1·10  0·5  1·02  0·92- 
